Qunmin Zhou

This inventor holds 5 USPTO granted patents and 4 published patent applications and 3 EPO patents. Top assignees: Acroimmune Biotech Co., Ltd., Acroimmune Biopharma Co., Ltd., Hualan Genetic Engineering Co., Ltd.. Active years: 2017-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qunmin Zhou. Retrieved from https://idiyas.com/inventor/qunmin-zhou

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 4)

% Patents Active = 100.0

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 7.1

ph-index = 2

Forward Citations = 5(Granted Patents)

Location History:

Jiangsu, CN (2017)
Suzhou, CN (2022 - 2024)

Company Filing History:

2 out of 2

Acroimmune Biotech Co., Ltd.

patents

1 out of 1

Acroimmune Biopharma Co., Ltd.

patent

1 out of 1

Hualan Genetic Engineering Co., Ltd.

patent

4. 1 out of 1

Suzhou Stainwei Biotech Inc.

patent

Years Active: 2017-2024

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11976129 - Monoclonal antibody specifically binding human and monkey CD38 antigens, preparation method and use thereof (2024-05-07),

2. 11897955 - Monoclonal antibody binding to TIGIT antigen, preparation method and use thereof (2024-02-13),

3. 11666659 - Monoclonal antibody specifically binding to human plasmalemma vesicle-associated protein PV-1, preparation and use thereof (2023-06-06),

4. 11345754 - Monoclonal antibody antagonizing and inhibiting the binding of human PD-1 antigen to its ligand, preparation method therefor and application thereof (2022-05-31),

5. 9580498 - Monoclonal antibody for antagonizing and inhibiting binding of vascular endothelial growth factor to its receptor, and coding sequence (2017-02-28),

Title: Innovations of Qunmin Zhou in Monoclonal Antibody Development

Introduction

Qunmin Zhou is a prominent inventor based in Suzhou, China, known for his significant contributions to the field of biotechnology. He holds a total of five patents, focusing primarily on monoclonal antibodies that target specific antigens for therapeutic applications. His work has the potential to advance treatments for various tumors and diseases.

Latest Patents

One of Qunmin Zhou's latest patents is a monoclonal antibody specifically binding to human and monkey CD38 antigens. This invention includes detailed amino acid sequences for the complementarity-determining regions of both the light and heavy chain variable regions of the antibody. The monoclonal antibody can be utilized in pharmaceutical compositions for treating tumors with positive CD38 expression, such as human myeloma and lymphoma.

Another notable patent involves a monoclonal antibody that binds to the human TIGIT antigen. This antibody has high affinity and antagonistically inhibits the binding of TIGIT to its ligand, CD155. The patent outlines the amino acid sequences for the complementarity-determining regions of the antibody, along with a humanization preparation method. This antibody can also be used in pharmaceutical compositions for treating various tumors.

Career Highlights

Qunmin Zhou has worked with several companies in the biotechnology sector, including Acroimmune Biotech Co., Ltd. and Acroimmune Biopharma Co., Ltd. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.

Collaborations

Throughout his career, Qunmin Zhou has collaborated with notable professionals in the field, including Hongqun Hu and Zui Chen. These collaborations have likely enhanced his research and development efforts in monoclonal antibody technology.

Conclusion

Qunmin Zhou's innovative work in monoclonal antibody development showcases his commitment to advancing medical treatments. His patents reflect a deep understanding of biotechnology and its applications in treating serious diseases.

Profile summary based on public USPTO records.